구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Amivantamab |
Overview Company | Janssen |
Overview Modality | ANTIBODY |
Overview Target | Colorectal Cancer |
Overview Indication | Carcinoma, Non-Small-Cell Lung |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | unique structural alterations that lock the αC-helix in an active orientation, creating steric hindrance within the drug |
Positioning Known limitation | resistance to first-, second- and third-generation EGFR tyrosine kinase inhibitors (TKIs) due to unique structural alterations that l |
MoA Mechanism | targeting epidermal growth factor and mesenchymal-epithelial transition receptor |
MoA Biomarker | EGFR and ALK Positive |
PK/PD Half-life | 14 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Interstitial Lung Disease (ILD)/Pneumonitis : Monitor for new or worsening symptoms indicative of |
Clinical Safety signal | Interstitial Lung Disease (ILD)/Pneumonitis : Monitor for new or worsening symptoms indicative of |
Clinical Selected reported efficacy | ORR 4.3% |
Clinical Reported ORR | 4.3% |
Clinical Result source | ClinicalTrials.gov NCT04945733 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT04945733 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Amivantamab |
Overview Company | Janssen |
Overview Modality | ANTIBODY |
Overview Target | Colorectal Cancer |
Overview Indication | Carcinoma, Non-Small-Cell Lung |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | unique structural alterations that lock the αC-helix in an active orientation, creating steric hindrance within the drug |
Positioning Known limitation | resistance to first-, second- and third-generation EGFR tyrosine kinase inhibitors (TKIs) due to unique structural alterations that l |
MoA Mechanism | targeting epidermal growth factor and mesenchymal-epithelial transition receptor |
MoA Biomarker | EGFR and ALK Positive |
PK/PD Half-life | 14 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Interstitial Lung Disease (ILD)/Pneumonitis : Monitor for new or worsening symptoms indicative of |
Clinical Safety signal | Interstitial Lung Disease (ILD)/Pneumonitis : Monitor for new or worsening symptoms indicative of |
Clinical Selected reported efficacy | ORR 4.3% |
Clinical Reported ORR | 4.3% |
Clinical Result source | ClinicalTrials.gov NCT04945733 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT04945733 |
추천 비교
추천 비교